EyePoint Pharmaceuticals Inc (NAS:EYPT)
$ 11.13 -0.03 (-0.27%) Market Cap: 579.70 Mil Enterprise Value: 286.54 Mil PE Ratio: 0 PB Ratio: 2.22 GF Score: 55/100

Q3 2022 EyePoint Pharmaceuticals Inc Earnings Call Transcript

Nov 02, 2022 / 12:30PM GMT
Release Date Price: $5.13 (-5.35%)
Operator

Welcome to the EyePoint Third Quarter 2022 Financial Results conference call. (Operator Instructions) As a reminder, today's conference call is being recorded.

I will now turn the conference over to your host Mr. George Elston, Chief Financial Officer of EyePoint Pharmaceuticals. Please go ahead, sir.

George O. Elston
EyePoint Pharmaceuticals, Inc. - CFO

Thank you. And thank you all for joining us on today's conference call to discuss EyePoint Pharmaceuticals Third Quarter 2022 Financial Results and recent corporate developments. With me today are Nancy Lurker, President and Chief Executive Officer; Dr. Jay Duker, Chief Operating Officer; and Scott Jones, Chief Commercial Officer. Nancy will begin with a review of recent corporate updates. Dr. Duker will then discuss Phase II clinical trials for EYP-1901 and Scott will comment on our third quarter 2022 financial performance -- commercial performance. I will close with commentary on the third quarter of 2022 financial results and we will then open up the call for your questions.

Earlier this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot